Condition: SCLC · SCLC, Extensive Stage · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
This is an open-label, single-arm, phase 2 study to evaluate the safety and efficacy of golidocitinib with PD-1 inhibitors as maintenance treatment in patients with previously untreated extensive-stage small cell lung cancer.
This description comes directly from the study's public registry record.
Zhijie Wang, MD, PhD · +86 010-67781331 · jie_969@163.com
Boyang Sun · +8613002235072 · boyangsun926@163.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
| Xinqiao Hospital, Third Military Medical University | Chongqing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07110103